Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > REGULATORY
REGULATORY
- Editor’s Pick: Five Healthcare Policy News Headlines for October
November 6, 2015
- 4 PMDA Advisors to Resign over Conflicts of Interest
November 6, 2015
- AMED Now Taking Applications for Pre-Orphan Designation Scheme
November 6, 2015
- Chuikyo Payer Rep Urges Further Price Cuts for Long-Listed Products with Low Generic Rates
November 5, 2015
- Chuikyo Doctor Reps Positive, but Payers Wary about Industry’s Ideas on “Essential Drugs”
November 5, 2015
- AMED Aims to Give Society Access to Results of Research in Genomic Medicine: President
November 5, 2015
- Pricing Rule for Essential Drugs Top Priority in FY2016 Reform: Ex-MHLW Economic Affairs Head
November 4, 2015
- PMDA Reviewing Opdivo for Risk of Type 1 Diabetes
November 4, 2015
- PAFSC 1st Committee Recommends Approval for Social Anxiety Disorder for Lexapro
November 4, 2015
- MHLW Weighs Another Business Improvement Order to Novartis
November 4, 2015
- Fiscal System Council Approves MOF’s Proposal for NHI Pricing System Reform
November 2, 2015
- MOF Proposes Full Implementation of Cost-Effective Assessments as Precondition for Full-Scale Introduction of Premium for New Drug Development
November 2, 2015
- Takeda’s Hib Vaccine to Be Reported to PAC in December
November 2, 2015
- PAFSC’s 2nd Committee Receives Report on Add’l Indication for Xeloda, Elplat
November 2, 2015
- MOF Asks Fiscal System Council to Issue Conclusion on Market Price Survey for FY2017 Revision “by Mid-2016 at Latest”
November 2, 2015
- 30% of Generic Companies Unable to Prepare Stable Supply Manuals by End of FY2014; MHLW Official Calls for Early Preparation
October 30, 2015
- Chuikyo Agrees to Tweak “Cost per Course of Treatment” Rule for Combo Drugs after Harvoni Debate
October 29, 2015
- Chuikyo Subcommittee Discusses Envisaged HTA Organization
October 29, 2015
- Chuikyo Sees Big Chorus for Further Reforms in Generic Pricing
October 29, 2015
- Some Chuikyo Subcommittee Members Call for Revision of Rules for Pricing of Biosimilars
October 29, 2015
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…